SCHEMBL4024035

SCHEMBL4024035

COC(=O)c1cccc(C(=O)C2CN(CC(=O)N(C)C)CC(C(=O)c3cccc(C(=O)OC)c3)C2c2cccc(F)c2C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
RBP4 P02753 1/20 0.36
IL2 P60568 1/20 0.35
AAK1 Q2M2I8 1/20 0.35
CYP11B1 P15538 2/20 0.34
CYP11B2 P19099 2/20 0.34
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
ERN1 O75460 1/20 0.33
GRM2 Q14416 1/20 0.33
EPHX2 P34913 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
JAK2 O60674 1/20 0.33
JAK3 P52333 1/20 0.33
PTK2 Q05397 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024037 1.00 ALDH1A1 (0.37) ALDH1A1MEN1KMT2ARBP4IL2
SCHEMBL4022580 0.96 ALDH1A1 (0.35) ALDH1A1MEN1KMT2ARBP4IL2
SCHEMBL4022581 0.96 ALDH1A1 (0.35) ALDH1A1MEN1KMT2ARBP4IL2
SCHEMBL5634573 0.93 ALDH1A1 (0.34) ALDH1A1MEN1KMT2ARBP4IL2
SCHEMBL4027956 0.89 KDM2B (0.43) ALDH1A1MEN1KMT2ALMNAL3MBTL1
SCHEMBL4027951 0.89 KDM2B (0.43) ALDH1A1MEN1KMT2ALMNAL3MBTL1
SCHEMBL4749448 0.89 EED (0.34) ALDH1A1MEN1KMT2A
SCHEMBL4024473 0.87 ABL1 (0.37) MEN1KMT2AMGLL
SCHEMBL4024477 0.87 ABL1 (0.37) MEN1KMT2AMGLL
SCHEMBL4019982 0.87 KMT2A (0.39) ALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 ALDH1A1 258/4885MEN1 77/4885KMT2A 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.